dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$sny', '$regn']
$regn $sny dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis 
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft